Ceribell's Investor Pitch: AI-Powered EEG Fuels Rapid Growth

SUNNYVALE, CA – February 18, 2026 – As medical technology firm Ceribell, Inc. (Nasdaq: CBLL) prepares for two high-profile investor conferences in March, the company is armed with a compelling narrative of rapid growth, accelerating market adoption, and a string of significant regulatory victories for its innovative neurological diagnostic platform. The upcoming presentations by company leadership are set to provide Wall Street with a detailed look into a strategy that is quickly positioning Ceribell as a disruptive force in acute neurological care.

Chief Financial Officer Scott Blumberg is scheduled to present at the Raymond James 47th Annual Institutional Investors Conference on March 2, followed by a fireside chat with both Blumberg and CEO and Co-founder Jane Chao, Ph.D., at the TD Cowen 46th Annual Health Care Conference on March 3. These events provide a critical platform for the company to articulate its vision and justify its growth-focused investments to the financial community, just days after its fourth-quarter and full-year 2025 earnings are due to be reported on February 24.

A Financial Picture of High-Growth Ambition

Investors will be keenly focused on Ceribell’s impressive financial trajectory. The company reported a 45% increase in total revenue for the full year 2024, reaching $65.4 million, up from $45.2 million in 2023. This momentum has continued, with the company raising its full-year 2025 revenue guidance to a range of $83 million to $87 million, which would represent a substantial 27% to 33% increase over 2024.

This robust top-line growth is supported by expanding gross margins, which improved to 87% in 2024 and hit 88% in the first quarter of 2025. While the company continues to operate at a net loss—reporting a $40.5 million loss in 2024—this is largely attributed to aggressive and strategic investments in its commercial organization and research and development. With a healthy cash reserve of $194.4 million at the end of 2024, Ceribell appears well-capitalized to fund its expansion and pursue a path to profitability without sacrificing its growth engine.

The company’s commercial strategy is clearly gaining traction. Ceribell ended 2024 with 529 active hospital accounts, a number that grew to 558 by the end of the first quarter of 2025. This steady increase in adoption is a primary driver of both its product and subscription revenue streams, demonstrating a successful “land and expand” model within health systems.

Beyond the Balance Sheet: Revolutionizing Neurological Care

Underpinning Ceribell’s financial success is a technological innovation that addresses a critical unmet need in acute care. Traditional electroencephalography (EEG) systems, the long-standing gold standard for detecting seizures, are often cumbersome, require specialized technicians, and can take hours to deploy—a critical delay in emergency rooms and intensive care units (ICUs) where time is brain.

The Ceribell System was designed to overcome these hurdles. It is a portable, point-of-care EEG platform that can be set up by a nurse or other provider in minutes. Its true power, however, lies in its sophisticated, AI-powered algorithms that provide real-time monitoring and alerts for neurological conditions, effectively aiming to make EEG a new vital sign.

The company’s innovation pipeline has been exceptionally productive over the past year, resulting in a cascade of regulatory approvals that significantly expand its clinical utility and addressable market:

• Pediatric and Neonatal Care: After receiving FDA 510(k) clearance in early 2025 for its pediatric Clarity™ algorithm, Ceribell became the first company with a seizure detection algorithm indicated for patients aged one and older. This was followed by a clearance for its use in neonates in November 2025, opening the door to some of the most vulnerable patient populations.

• Delirium Monitoring: In December 2025, Ceribell secured a first-of-its-kind FDA 510(k) clearance for a delirium monitoring solution, tackling a common and serious complication for ICU patients.

• Stroke Detection: Perhaps most significantly, the company received an FDA Breakthrough Device Designation in January 2026 for its Large Vessel Occlusion (LVO) Stroke Detection and Monitoring Solution. This designation is reserved for technologies that could provide more effective treatment for life-threatening conditions and will help accelerate its development and review.

Having already been used to treat over 200,000 patients, these new indications solidify the Ceribell System as a versatile platform technology, not just a single-purpose device.

The Point-of-Care Battleground

Ceribell is carving out its market share by offering a solution tailored to the chaotic, fast-paced environment of acute care, a setting where traditional EEG systems often fall short. By focusing on speed, ease of use, and actionable AI-driven insights, the company differentiates itself from established competitors like Natus Medical and Nihon Kohden, whose systems are often more complex.

The company’s stated goal is to penetrate a market of approximately 5,500 prospective hospital accounts in the U.S. Its current base of over 550 active accounts indicates that significant runway for growth remains. The investment in its commercial organization is a direct effort to capture this opportunity by educating physicians and hospital administrators on the clinical and economic benefits of rapid neurological assessment.

Further strengthening its strategic position, Ceribell became the first medical device company to achieve FedRAMP High authorization from the U.S. federal government in early 2025. This rigorous security clearance opens up a new and significant market within federal healthcare systems, including the Department of Veterans Affairs and Department of Defense hospitals.

The upcoming presentations offer Ceribell’s leadership a prime opportunity to weave these threads—strong financials, groundbreaking innovation, and a clear market expansion strategy—into a cohesive narrative for the investment community. Investors will be listening for details on how the company plans to leverage its recent FDA wins to accelerate adoption and how it will manage its operating expenses as it continues to scale. The story of Ceribell is evolving from that of a promising startup to that of a formidable player in medical technology, and the March conferences will be a key chapter in that evolution.